Xiaoming Zhang, Ph.D. has more than 20 years of experience in discovery and development of new molecular entities across multiple therapeutic areas.

Prior to joining Menlo Therapeutics Inc., he was a venture partner at Velocity Pharmaceutical Development, where he played an integral role in the launching and building of several project focused companies, including Menlo Therapeutics Inc., Corsair and Spitfire.

In 2010, he cofounded Theron Pharmaceuticals, a clinical stage company developing a best-in-class bronchodilator for the treatment of COPD and uncontrolled asthma. He was previously the Senior Director of Chemistry at CoMentis Inc.

In this capacity, he spearheaded cognition research effort targeting Alzheimer’s disease and cognitive deficit associated with schizophrenia.

Previously, Dr. Zhang served as Director of Medicinal Chemistry at Millennium Pharmaceuticals, Portola and ARYx, where he successfully led the discovery and development of a number of new molecular entities, notably elinogrel and tecarfarin. Earlier in his career, Dr. Zhang was a research scientist and program leader at Roche.

Dr. Zhang received a PhD from University of Maryland, College Park, in the field of synthetic organic chemistry and pursued postdoctoral research at University of California, Berkeley.

He is an inventor on 25 US patents.